01—Abstract
Summary
Summary of the 8-K filed January 20, 2026. Cited figures are marked; the original filing is the authoritative source.
3M reported fourth-quarter and full-year 2025 results on January 20, 2026, and initiated full-year 2026 guidance.
Q4 GAAP sales were $6.1 billiona, up 2.1% year-on-year, with organic growth of only 0.6%; GAAP EPS fell 20% to $1.07 and GAAP operating margin compressed 510 bps to 13.0%, driven largely by special items such as significant litigation costs ($0.56 per share) and manufactured PFAS products ($0.39). On an adjusted basis, Q4 sales were $6.0 billion (up 3.7%, adjusted organic growth 2.2%), adjusted operating margin expanded 140 bps to 21.1%, and adjusted EPS rose 9% to $1.83. Full-year GAAP EPS was $6.00 (down 17%), while adjusted EPS was $8.06 (up 10%) on adjusted organic growth of 2.1% and a 200 bps margin expansion to 23.4%.
The key investor consideration is the gap between adjusted and GAAP results. Litigation-related charges were the dominant drag: full-year net litigation costs were $1.95b per share and cash litigation payments were roughly $3.5 billion pre-tax in 2025, sharply reducing operating cash flow to $2.3 billion versus adjusted free cash flow of $4.4 billion. Management is leaning on the adjusted metrics, and investors should weigh how much of the recurring PFAS and Combat Arms-related burden is truly non-recurring.
Cash returns were substantial, with $4.8 billionc returned to shareholders via dividends and buybacks in 2025, while total debt and cash positions also shifted over the year. For 2026, 3M guided to adjusted organic sales growth of about 3%, total sales growth of about 4%, an adjusted operating margin expansion of 70 to 80 bps, and adjusted EPS of $8.50 to $8.70. Adjusted operating cash flow is expected at $5.6 to $5.8 billion, implying adjusted free cash flow of $4.6 to $4.8 billion and conversion above 100%.
Management reiterated its path toward meeting or exceeding 2027 commitments from its Investor Day. Guidance excludes unforecastable special items, so GAAP results are likely to remain materially below adjusted figures in 2026.
02—Key points
Key Highlights
- Q4 2025 GAAP EPS fell 20% to $1.07 and GAAP operating margin fell 510 bps to 13.0%, primarily due to special items including litigation costs ($0.56/share) and PFAS-related charges ($0.39/share).
- Q4 2025 adjusted EPS rose 9% to $1.83, with adjusted operating margin up 140 bps to 21.1% and adjusted organic sales growth of 2.2%.
- Full-year 2025 adjusted EPS of $8.06 (up 10%) versus GAAP EPS of $6.00 (down 17%); special items were $2.06 per share, led by $1.95 of significant litigation costs.
- Full-year 2025 GAAP sales of $24.9 billion (up 1.5%) and adjusted sales of $24.3 billion (up 2.7%), with adjusted organic growth of 2.1%.
- Operating cash flow of $2.3 billion versus adjusted free cash flow of $4.4 billion; 2025 litigation cash payments of roughly $3.5 billion pre-tax weighed heavily on reported cash generation.
- 2026 guidance: adjusted organic sales growth of ~3%, total sales growth of ~4%, adjusted operating margin expansion of 70–80 bps, and adjusted EPS of $8.50–$8.70.
- 3M returned $4.8 billion to shareholders in 2025 via dividends and share repurchases, while shares outstanding declined from about 539.5 million to 530.3 million.
03—Questions
Frequently Asked Questions
Why is there such a large gap between GAAP and adjusted EPS for 3M in 2025?
The gap is driven by special items that management excludes from adjusted results. In 2025, these included $1.95 per share of significant litigation costs (primarily PFAS-related and Combat Arms Earplugs matters), $0.47 per share from manufactured PFAS products, $0.29 per share from business divestiture losses, and $0.13 from transformation costs, partly offset by a $0.78 per share gain from the increased value of its Solventum ownership. Investors should assess whether these charges are truly non-recurring, given that litigation costs have affected results for several years.
How much cash did 3M actually generate from operations in 2025?
Net cash from operating activities was $2.3 billion in 2025, well below adjusted free cash flow of $4.4 billion. The difference reflects roughly $2.8 billion of after-tax litigation payments and other special-item cash outflows, which 3M excludes from its adjusted free cash flow measure. Capital expenditures were $910 million on a GAAP basis.
What does 2026 guidance imply for 3M's earnings and cash flow?
Management guides to adjusted EPS of $8.50–$8.70, adjusted organic sales growth of about 3%, and a 70–80 bps adjusted operating margin expansion. Adjusted operating cash flow is expected at $5.6–$5.8 billion, with adjusted free cash flow of $4.6–$4.8 billion and conversion above 100%. Because special items such as litigation costs cannot be reliably forecast, 3M does not provide GAAP guidance, so reported results will likely differ materially from these adjusted figures.
Is 3M's core business growing?
On an adjusted basis, yes, modestly. Full-year 2025 adjusted organic growth was 2.1%, and Q4 adjusted organic growth accelerated to 2.2%. On a GAAP basis, however, organic sales grew only 0.9% for the year and 0.6% in Q4. Growth was strongest in Safety and Industrial (organic sales up 3.2% for the year), while Transportation and Electronics declined on a GAAP basis (organic down 1.5%) and Consumer was roughly flat.
How is 3M returning capital to shareholders?
3M returned $4.8 billion to shareholders in 2025 through dividends and share repurchases, and shares outstanding fell from about 539.5 million at year-end 2024 to 530.3 million at year-end 2025. Investors should note that 2025 cash was supported by $1.6 billion of proceeds from treasury stock issuances under stock option and benefit plans, and that returns are being made while litigation cash outflows remain large.
04—Continue